First patients dosed in trial for Ultra-Rare kidney disorder
Disease control
Recruiting now
This is the first time a new drug called CPV-104 is being tested in people. The study aims to see if it is safe and how the body handles it in healthy adults and in patients with C3 glomerulopathy (C3G), a very rare and serious kidney disease. The main goal is to check for side e…
Phase: PHASE1 • Sponsor: eleva GmbH • Aim: Disease control
Last updated Apr 02, 2026 02:26 UTC